| scholarly article | Q13442814 |
| P50 | author | Susan M. Ramin | Q110252023 |
| P2093 | author name string | Hong Zhang | |
| Yang Xia | |||
| Tiejuan Mi | |||
| Yujin Zhang | |||
| M John Hicks | |||
| Rodney E Kellems | |||
| Roxanna A Irani | |||
| Edwina J Popek | |||
| Cissy C Zhou | |||
| P2860 | cites work | Angiotensin receptors, autoimmunity, and preeclampsia | Q24605647 |
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 | ||
| Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. | Q34702420 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia | Q35681821 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| The uterine spiral arteries in human pregnancy: facts and controversies | Q36401771 | ||
| The renin-angiotensin-aldosterone system in preeclampsia. A review | Q36453940 | ||
| Inflammation and pre-eclampsia | Q36530771 | ||
| Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. | Q43576536 | ||
| Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction | Q43744794 | ||
| High-salt diet enhances vascular reactivity in pregnant rats with normal and reduced uterine perfusion pressure | Q43744797 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia | Q44413491 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Fetal growth retardation in infants of multiparous and nulliparous women with preeclampsia | Q46665406 | ||
| Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion | Q46877931 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| The preeclampsia enigma and the renin-angiotensin system. | Q52972348 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. | Q54661322 | ||
| Urinary Placental Growth Factor and Risk of Preeclampsia | Q56619498 | ||
| Dysregulation of the Circulating and Tissue-Based Renin-Angiotensin System in Preeclampsia | Q56981959 | ||
| Pre-eclampsia in second pregnancy | Q70057283 | ||
| Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen | Q71695937 | ||
| Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure | Q73567364 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression | Q81411178 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| autoantibody | Q785022 | ||
| maternal health | Q6786626 | ||
| P304 | page(s) | 855-862 | |
| P577 | publication date | 2008-07-27 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | |
| P478 | volume | 14 |
| Q28069689 | A Dormant Microbial Component in the Development of Preeclampsia |
| Q43195589 | A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring |
| Q38126570 | A complicated role for the renin-angiotensin system during pregnancy: highlighting the importance of drug discovery |
| Q36752126 | A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice |
| Q54361188 | A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. |
| Q36115311 | A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model |
| Q33737551 | A new mouse model to explore therapies for preeclampsia |
| Q38246351 | A potential pathophysiological role for galectins and the renin-angiotensin system in preeclampsia |
| Q37257615 | A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia |
| Q34870775 | A2B adenosine receptor-mediated induction of IL-6 promotes CKD. |
| Q53700889 | AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. |
| Q38118625 | Activating autoantibodies and cardiovascular disease |
| Q35994304 | Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats |
| Q36317153 | Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma |
| Q38082526 | Adaptive immune responses during pregnancy |
| Q37800883 | Aetiology and physiopathology of preeclampsia and related forms |
| Q28590130 | Af17 deficiency increases sodium excretion and decreases blood pressure |
| Q34541831 | Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor Enhance Angiotensin II-Induced Renal Vascular Sensitivity and Reduce Renal Function During Pregnancy |
| Q43291018 | Agonistic antibody to the alpha1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein |
| Q39409827 | Agonistic autoantibodies to the α(1) -adrenergic receptor and the β(2) -adrenergic receptor in Alzheimer's and vascular dementia |
| Q90050388 | Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy |
| Q34714082 | Angiogenic factors and preeclampsia |
| Q83351577 | Angiogenic factors and preeclampsia |
| Q37935034 | Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia |
| Q54041753 | Angiogenic, Antiangiogenic Molecules, and Bioactive Lipids in Preeclampsia. |
| Q90305559 | Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism |
| Q36039299 | Angiotensin II revisited: new roles in inflammation, immunology and aging |
| Q35576417 | Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction |
| Q36683260 | Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q64111458 | Angiotensin II type i receptor agonistic autoantibodies induces apoptosis of cardiomyocytes by downregulating miR21 in preeclampsia: a mechanism study |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q33748680 | Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity |
| Q34040304 | Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia |
| Q33748650 | Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia |
| Q43939628 | Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction |
| Q37816496 | Animal models of pre-eclampsia. |
| Q46300987 | Animal models of preeclampsia: translational failings and why. |
| Q28534198 | Antibodies against AT1 receptors are associated with vascular endothelial and smooth muscle function impairment: protective effects of hydroxysafflor yellow A |
| Q34364148 | Antibodies to the α1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography |
| Q37000033 | Apoptotic and stress signaling markers are augmented in preeclamptic placenta and umbilical cord |
| Q37307973 | Are we getting closer to a Nobel prize for unraveling preeclampsia? |
| Q50077615 | Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker? |
| Q34473885 | Autoantibodies and cardiovascular dysfunction: cause or consequence? |
| Q37689681 | Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q36050771 | Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling |
| Q34040357 | Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia |
| Q94311716 | Autoimmune disease: pre-eclampsia IgG produces a murine model of maternal morbidity |
| Q36357099 | Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary? |
| Q37699015 | Characterization of antibody specificities associated with preeclampsia |
| Q79803704 | Common reproductive disorders may have immunological basis |
| Q30409861 | Complement activation is critical for placental ischemia-induced hypertension in the rat. |
| Q51464431 | Complement component C1q as potential diagnostic but not predictive marker of preeclampsia. |
| Q38220404 | Constitutive activity in the angiotensin II type 1 receptor: discovery and applications |
| Q50131577 | Current model systems for the study of preeclampsia. |
| Q30525576 | DBA-lectin reactivity defines mouse uterine natural killer cell subsets with biased gene expression |
| Q36818005 | Detrimental effects of adenosine signaling in sickle cell disease |
| Q34544386 | Differential expression of microRNAs in decidua-derived mesenchymal stem cells from patients with pre-eclampsia |
| Q34731047 | Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia |
| Q35740222 | Domain coupling in GPCRs: the engine for induced conformational changes |
| Q92235464 | Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens |
| Q39450324 | Effect on the production of soluble endoglin from human choriocarcinoma cells by preeclampsia sera |
| Q33392329 | Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction |
| Q36575572 | Elevated Endothelial Hypoxia-Inducible Factor-1α Contributes to Glomerular Injury and Promotes Hypertensive Chronic Kidney Disease |
| Q36836373 | Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia |
| Q36575544 | Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia |
| Q36245112 | Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications |
| Q33740993 | Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia |
| Q36351174 | Four Pathways Involving Innate Immunity in the Pathogenesis of Preeclampsia |
| Q39223093 | From apelin to exercise: emerging therapies for management of hypertension in pregnancy |
| Q38056887 | From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system? |
| Q35362708 | Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice |
| Q38151169 | Future therapies for pre-eclampsia: beyond treading water |
| Q49751930 | Hepatic dysfunction and thrombocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase |
| Q50155675 | Highly tamoxifen-inducible principal-cell-specific Cre mice with complete fidelity in cell specificity and no leakiness |
| Q37447371 | Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. |
| Q35029700 | Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes |
| Q38110492 | Hypertension: physiology and pathophysiology |
| Q36879266 | Hypoxia-independent upregulation of placental hypoxia inducible factor-1α gene expression contributes to the pathogenesis of preeclampsia |
| Q53433801 | Identification of a Novel Agonist-Like Autoantibody in Preeclamptic Patients. |
| Q49600503 | Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities |
| Q39837503 | Immunoadsorption of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients With Mild to Moderate Dementia |
| Q64977878 | Immunology of Uterine and Vaginal Mucosae: (Trends in Immunology 39, 302-314, 2018). |
| Q36662338 | Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q94464397 | Innate and Adaptive Immune Responses in HELLP Syndrome |
| Q58795465 | Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia |
| Q37010679 | Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia |
| Q48641988 | Interleukin 22 Promotes Blood Pressure Elevation and Endothelial Dysfunction in Angiotensin II-Treated Mice |
| Q37346569 | Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage |
| Q33907972 | Interleukin-33-induced expression of PIBF1 by decidual B cells protects against preterm labor |
| Q36241932 | International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. |
| Q36050775 | Is preeclampsia an autoimmune disease? |
| Q37921853 | Lifting the lid on GPCRs: the role of extracellular loops |
| Q33855316 | Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor |
| Q64115613 | Limited AT1 Receptor Internalization Is a Novel Mechanism Underlying Sustained Vasoconstriction Induced by AT1 Receptor Autoantibody From Preeclampsia |
| Q38303854 | Limited evidence for calcium supplementation in preeclampsia prevention: a meta-analysis and systematic review |
| Q89454188 | Lipoxin A4 suppresses angiotensin II type 1 receptor autoantibody in preeclampsia via modulating caspase-1 |
| Q38972879 | Long Non-Coding RNA MALAT1 Promotes Proliferation, Angiogenesis, and Immunosuppressive Properties of Mesenchymal Stem Cells by Inducing VEGF and IDO. |
| Q53300122 | Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia |
| Q35053657 | Maternal treatment with agonistic autoantibodies against type-1 angiotensin II receptor in late pregnancy increases apoptosis of myocardial cells and myocardial susceptibility to ischemia-reperfusion injury in offspring rats |
| Q37383975 | Maternal uterine vascular remodeling during pregnancy |
| Q46342648 | Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia |
| Q50937792 | Mechanism of agonistic angiotensin II type I receptor autoantibody-amplified contractile response to Ang II in the isolated rat thoracic aorta. |
| Q37285199 | Mechanism of hypoxia-induced GCM1 degradation: implications for the pathogenesis of preeclampsia |
| Q37103549 | Mechanisms and management of hypertension in pregnant women |
| Q37211008 | Mechanisms and potential therapies for preeclampsia |
| Q37136212 | Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q37698191 | Membranous nephropathy: recent travels and new roads ahead |
| Q35099504 | Mesenchymal stem cells ameliorate Th1-induced pre-eclampsia-like symptoms in mice via the suppression of TNF-α expression |
| Q58589187 | Molecular Determinants of Microvascular Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q54901493 | Molecular Mechanisms of Preeclampsia. |
| Q92647210 | Narrowing abdominal aorta and vein is a simple and useful method for preparing a mice model of gestational hypertension |
| Q27010670 | New approaches for managing preeclampsia: clues from clinical and basic research |
| Q33935675 | New developments in the pathogenesis of preeclampsia |
| Q35175458 | Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbit |
| Q34365552 | Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1α pathway |
| Q38017497 | Pathogenesis of pre-eclampsia: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome |
| Q26865332 | Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology |
| Q56794716 | Placental Protein 13 and Decidual Zones of Necrosis: An Immunologic Diversion That May be Linked to Preeclampsia |
| Q37114991 | Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections |
| Q35558666 | Placental lesions associated with acute atherosis |
| Q38649387 | Potential New Non-Invasive Therapy Using Artificial Oxygen Carriers for Pre-Eclampsia |
| Q33419126 | Pre-eclampsia has an adverse impact on maternal and fetal health |
| Q33416340 | Pre-eclampsia part 1: current understanding of its pathophysiology |
| Q91815900 | Pre-eclampsia: pathogenesis, novel diagnostics and therapies |
| Q35143007 | Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease |
| Q43744904 | Preeclampsia-associated stresses activate Gadd45a signaling and sFlt-1 in placental explants |
| Q64926884 | Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches. |
| Q36965155 | Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines |
| Q43699926 | Preeclampsia: effect on newborn blood pressure in the 3 days following preterm birth: a cohort study |
| Q35665007 | Preeclampsia: multiple approaches for a multifactorial disease |
| Q37512886 | Preeclampsia: the role of angiogenic factors in its pathogenesis |
| Q37832764 | Preeclamptic nephropathy |
| Q37354268 | Pregnancy outcomes after kidney donation |
| Q37879823 | Pregnancy-associated homeostasis and dysregulation: lessons from genetically modified animal models |
| Q36556973 | Preparation and Biological Activity of the Monoclonal Antibody against the Second Extracellular Loop of the Angiotensin II Type 1 Receptor |
| Q42701351 | Progress toward identifying potential markers for preeclampsia: role of agonistic autoantibody to the angiotensin II type I receptor |
| Q81752844 | Putting pressure on pre-eclampsia |
| Q36537709 | RAS in Pregnancy and Preeclampsia and Eclampsia |
| Q39136791 | Recent Advances in Immunity and Hypertension |
| Q34404445 | Recent insights into the pathophysiology of preeclampsia |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q57254079 | Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia |
| Q37451538 | Regulatory T cells ameliorate intrauterine growth retardation in a transgenic rat model for preeclampsia |
| Q33411571 | Renal function in normal and disordered pregnancy |
| Q92071252 | Renal natural killer cell activation and mitochondrial oxidative stress; new mechanisms in AT1-AA mediated hypertensive pregnancy |
| Q35743816 | Renin angiotensin signaling in normal pregnancy and preeclampsia |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q47923741 | Renin-angiotensin system transgenic mouse model recapitulates pathophysiology similar to human preeclampsia with renal injury that may be mediated through VEGF. |
| Q47546316 | Role and mechanism of AT1-AA in the pathogenesis of HELLP syndrome |
| Q41653771 | Role of IgM and angiotensin II Type I receptor autoantibodies in local complement activation in placental ischemia-induced hypertension in the rat. |
| Q37067705 | Role of agonistic autoantibodies against type-1 angiotensin II receptor in the pathogenesis of retinopathy in preeclampsia |
| Q34785813 | Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia |
| Q33783531 | Role of biomarkers in early detection of preeclampsia |
| Q27022988 | Role of corin and atrial natriuretic peptide in preeclampsia |
| Q24308003 | Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy |
| Q34254466 | Sera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay |
| Q35592165 | Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. |
| Q52871208 | TGF-β3-induced miR-494 inhibits macrophage polarization via suppressing PGE2 secretion in mesenchymal stem cells. |
| Q34169819 | Targeted expression of Cre recombinase provokes placental-specific DNA recombination in transgenic mice |
| Q46329692 | Targeted inhibition of complement activation prevents features of preeclampsia in mice |
| Q52715243 | The Role of Interleukin-10 in the Pathophysiology of Preeclampsia. |
| Q47577568 | The agonistic autoantibodies to the angiotensin II type 1 receptor in pregnancies complicated by hypertensive disorders |
| Q35037064 | The biology of preeclampsia |
| Q33591058 | The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia |
| Q36407259 | The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy |
| Q38693025 | The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia |
| Q33957722 | The immune system in hypertension |
| Q53064232 | The immune system in hypertension. |
| Q38014802 | The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms |
| Q46308477 | The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia |
| Q38076773 | The role of B cells in pregnancy: the good and the bad. |
| Q48284671 | Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection. |
| Q38592484 | Thrombosis during pregnancy: Risks, prevention, and treatment for mother and fetus--harvesting the power of omic technology, biomarkers and in vitro or in vivo models to facilitate the treatment of thrombosis. |
| Q33737470 | Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification |
| Q27024986 | To B or not to B cells-mediate a healthy start to life |
| Q37240779 | Transglutaminase is a Critical Link Between Inflammation and Hypertension |
| Q34987180 | Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model |
Search more.